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en by a small subset (less than 5%) of highly tumorigenic 
cells with self-renewal properties, analogous to organ-
specifi c stem cells, and called cancer stem cells (CSCs)6. 
According to this model, only the CSCs, but not the re-
maining cells in the tumor, can propagate tumorigenesis7. 
If CSCs retain the features of tissue stem cells, being rare 
and entering the cell cycle infrequently, they could consti-
tute a population that is intrinsically resistant to current 
therapies designed to kill rapidly dividing cells3. CSCs 
have the capacity to divide and expand the cancer stem 
cell pool and to differentiate into the heterogeneous non-
tumorigenic cancer cell types8. If this hypothesis is cor-
rect, researchers should be refocused their interest on the 
minority stem cell population that fuels tumor growth. 
Effective tumor eradication will require obtaining agents 
Introduction
Ovarian cancer represents the most lethal of all gyne-
cologic malignancies. It is an aggressive disease associ-
ated with rapid progression to peritoneal metastases, and 
poor prognosis for patients1,2. Because of lack of early 
symptoms as well as effective screening, the majority of 
patients are diagnosed at an advanced stage. Nearly 75% 
of all patients at stage III or IV disease will achieve a 
complete clinical remission with primary surgery followed 
by platinum/taxane based chemotherapy. But 85–90% of 
patients at advanced stage will have recurrence and die 
of their disease3–5.
The mechanisms underlying chemoresistance in can-
cer are not clear. One hypothesis is that cancers are driv-
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A B S T R A C T
The cancer stem cells (CSCs) represent a minority of tumor cells that are able to proliferate and self-renew and might 
be responsible for tumor initiation and maintenance. The CD133 and CD117 are the most commonly used markers for the 
putative CSCs, especially for the ovarian CSCs, but its clinical signifi cance remains uncertain. The aim of this study was 
to compare the immunohistochemical  expression of CD133 and CD117 in 64 primary ovarian high grade serous carci-
noma and peritoneal metastasis, and to examine their potential clinical role. CD133 expression was mainly seen in the 
apical/endoluminal cell surface of tumor cells and was found in 61% of the carcinoma samples and 41% of the metastasis. 
The median of CD133 positive cells in tumors was 1 (0.1–7)%, and in metastases was 0.6 (0.1–6) %. CD117 expression 
appeared as a cytoplasmic and/or membranous stain and was found in 81% of the carcinoma samples and 77% of the 
metastasis. The median of CD117 positive cells in tumors was 1 (0.1–8)%, and in metastases was 0.1 (0.1–7)%. Multi-
variate analysis has shown that patients with high CD133 expression in tumor cells have signifi cantly shorter disease 
free survival and overall survival (p=0.025 and p=0.014, respectively). Patients with high CD117 expression in tumor cells 
have signifi cantly shorter disease free survival (p=0.031). Cox´s proportional hazards model identifi ed expression of CD133 
protein in tumor as an independent prognostic factor. Our study indicates that the immunohistochemical assessment of 
CD133 and CD117 expression may have potential clinical value in predicting disease progression and prognosis in the 
high grade serous ovarian cancer. CD133 proved to be an independent prognostic factor in the high grade serous ovarian 
cancer patients.
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that can target cancer stem cells while sparing normal 
stem cells9.
Putative CSCs can be isolated based on either a surface 
marker or an intracellular enzyme activity and then as-
sessed by a sphere-forming assay in non-adherent culture 
or by their ability to initiate new tumor growth when xe-
notransplanted into immunocompromised mice10. The 
most commonly used markers for CSCs are: ALDH,Bmi1
,CD24,CD44,CD90,CD105,CD117,CD133,CD166, 
EpCAM,SP, but there is no apparent consensus about the 
„best marker“ for any particular cancer11.
Cancer stem cells were initially isolated from blood 
cancers12. Cells within solid tumors are less accessible and 
cell surface markers required to isolate such cells are dif-
fi cult to identify6.  Over the past decade CSCs have been 
identifi ed for various epithelial malignancies including 
cancers of the breast, lung, pancreas, colon and pros-
tate7,13–17. Cell surface antigen profi le expression is defi ned 
by fl ow cytometry and immunohistochemistry techniques. 
Some studies investigated the clinical role of the immuno-
histochemically assessed CSCs; unfavorable prognostic 
role of high CSCs expression and connection with resis-
tance to radiotherapy and chemotherapy have been recog-
nized16,18–21. This assumes that high proportion of CSCs 
signifi es a worse prognosis. A role for CSCs in propagating 
and maintaining metastasis has been proposed22. It is sup-
posed that cell lines in the primary tumors and in the 
metastasis are derived from the same lineage of cancer 
stem cells23.
There is still uncertainty relating to the identifi cation 
of CSCs in ovarian cancer7. The most commonly used 
markers are: CD44, CD117, CD13311,24–26. Bapat et al. fi rst 
present the evidence that aggressiveness of human ovar-
ian cancer may be a result of transformation and dysfunc-
tion of stem cells in the ovary1. The ovarian cancer-initi-
ating cells are also isolated from human ovarian primary 
tumor tissues and showed up-regulation of the CD44 and 
CD11724,26,27. The CD133 positive cells were detected in 
ovarian cancer cell lines, in primary cancers and from 
ascitic fl uid, also in serous and clear cell tumors25,28. Re-
cently, Luo et al. demonstrated that human ovarian cancer 
cells with the CD117+ phenotype possess the unique prop-
erties of CSCs (self-renewal, differentiation, tumorigenic 
potential and chemoresistance)29.
CD133 is the human homologue of mouse prominin-1, 
a penta-membrane glycoprotein and a cell surface protein 
originally found on neuroepithelial stem cells in mice. It 
is a 120kD protein with fi ve transmembrane domains and 
two large glycosylated extracellular loops30. The function 
in cancer stem cells has not been established, but it has 
been found to interact with cholesterol and may be in-
volved in maintaining membrane topology and membrane 
lipid composition. Its expression has been shown to be re-
stricted to plasma membrane protrusions in epithelial 
cells7. CD133+ phenotype was fi rst used to identify and 
isolate brain tumor stem cells in malignant tumors and 
now it has been used to defi ne the CSCs populations in 
diverse malignancies (lung, pancreas, liver, prostate, 
colorectal, gastric16,20,21,31,32). The CD133 antigen repre-
sents a useful molecule to select and enrich the population 
of ovarian tumor cells which have a higher clonogenic ef-
fi ciency and proliferative potential33. Two splice variants 
of CD133, CD133/1(akaAC133) and CD133/2(akaAC141) 
recognize different glycosylated epitopes and most studies 
use CD133/1.
CD117 (c-kit proto-oncogene) is a 145 kD transmem-
brane receptor tyrosine kinase that binds stem cell factor 
(SCF) and is an important regulator of cell growth. The 
c-kit/SCF interaction is important for the survival and 
development of stem cells involved in hematopoiesis, in 
pancreas development and in melanogenesis, but also pro-
motes tumor growth by promoting proliferation and pro-
tecting the tumor cell from death14. The c-kit gene product 
is expressed in a variety of normal human tissue cell 
types, including breast epithelium, germ cells, melano-
cytes, immature myeloid cells, and mast cells. In ovarian 
cancer samples it was noticed that cells with 117+ pheno-
type possess properties of CSCs and chemoresis-
tance1,24,29,34. Expression was common in mast cell disease, 
testicular germ cell tumors, endometrial carcinomas, thy-
roid carcinomas, small cell carcinomas, malignant mela-
nomas, and ovarian epithelial carcinomas. C-kit positivity 
is a defi ning feature of gastrointestinal stromal tumors35.
Since CD133 and CD117 are the most commonly used 
markers for putative CSCs, especially for ovarian CSCs, 
we are decided to analyze immunohistochemically as-
sessed expression of these two markers on the samples 
from high grade serous ovarian carcinoma and their peri-
toneal metastasis. Clinical signifi cance of CD133 and 
CD117 expression is still uncertain, so we analyzed the 
possible correlation between these two markers and clini-
cal factors, especially disease free survival and overall 
survival. To our knowledge, there are no existing studies 
that have compared the expression of the immunohisto-
chemically assessed markers CD133 and CD117 in pri-
mary ovarian carcinomas and their peritoneal metastasis 
in association with potential clinical role.
Patients and Methods
Patients´  data
The study included 64 patients diagnosed with ovarian 
high grade serous carcinoma between January 1995 and 
January 2008 who underwent surgery and treatment in 
the University Hospital Centre Rijeka, Croatia. The study 
included a retrospective collection of archival samples and 
clinical information of the patients. The protocol was ap-
proved by Hospital Ethical Commission. All patients had 
advanced disease and were staged according to FIGO clas-
sifi cation (International Federation of Gynecology and 
Obstetrics) as stage III or IV. All patients underwent pri-
mary surgery which included total abdominal hysterec-
tomy with bilateral salpingoophorectomy, omentectomy, 
pelvic and paraaortic lymphadenectomy and multiple peri-
toneal biopsies, followed by chemotherapy. Patients´ re-
cords were reviewed and clinical characteristics as well as 
follow-up data were noted. All histopathological samples 
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are reclassifi ed according to latest two-tier grading sys-
tem of serous ovarian cancer4. The primary ovarian high 
grade serous cancer samples and their peritoneal metas-
tasis samples were analyzed. Response to treatment was 
grouped into two categories. Complete and partial re-
sponse (reduction of the tumor and/or reduction of the CA 
125 serum level below 35 U/ml) were grouped together and 
classifi es as »Yes« (responders), cases with stabilization of 
disease (weak response and satisfactory general condition) 
or progression were classifi es as »No« (non-responders).
Immunohistchemistry 
Formalin-fi xed, paraffi n-embedded specimens from 64 
patients with serous high grade ovarian carcinoma were 
analyzed at the Department of Pathology, School of Medi-
cine University of Rijeka, Croatia. Tissue sections of pri-
mary tumors and their peritoneal metastases were imu-
nohistochemically examined for CD133 and CD117 
expression.
Immunohistochemical staining for CD133 and CD117 
protein was done on 4 μm sections from formalin-fi xed, 
paraffi n-embedded tissues placed on coated glass slides. 
After they were deparaffi nised in xylene and rehydrated 
conventionally, antigen retrieval was performed by incu-
bation in a pressurized heating chamber at 125°C for 30 
seconds in TrisEDTA buffer (pH9). For CD133 protein 
slides were incubated with primary antibody (monoclonal-
mouse, clone AC133; Milteny Biotec, Germany) diluted 
1:50 and incubated overnight at 4°C. For CD117 protein 
slides were incubated with primary antibody (polyclonal 
antibody, C-19, c-Kit; Santa Cruz Biotechnology, Santa 
Cruz, CA) diluted 1:200 and incubated overnight at 4°C. 
After 30 minutes incubation with secondary antibody (En-
vision), 10 minutes incubation with DAB+chromogen was 
performed. 
Immunohistochemical stained slides for CD133 and 
CD117 expression were independently analyzed by two 
investigators who were blinded to clinical data. The posi-
tive stained cells were counted in ten random and non-
overlapping fi elds at high magnifi cation (x200). The re-
sults were expressed as the percentage of total number of 
nuclei counted in the same fi elds28,36. For analysis of pro-
gression and survival patients were divided into three 
groups of CD133 and CD117 status: negative (0% of posi-
tive tumor cells), 0.1–0.9% (of positive tumor cells), and 
>0.9% (of positive tumor cells).
Statistical analysis
Statistical analysis of data was performed using Sta-
tistica for Windows, release 11.0 (StatSoft, Inc., Tulsa, 
OK). To analyze the distribution of all cases according to 
clinico-pathological characteristics was used ?2 test or t-
test for proportions. ?2 test was used to comparison the 
difference in distribution of cases CD133 and CD117 ex-
pression in tumor and metastasis according to clinico-
pathological characteristics. Disease free survival was 
calculated from the date of treatment to the date of pro-
gression (biochemical or clinical relapse or partial re-
sponse) and Overall survival was calculated from the date 
of treatment to the date of death or the date of last seen. 
The normality of the distribution of the disease free sur-
vival and overall survival, as the expression of examined 
markers, were checked by Kolmogorov-Smirnov test. The 
data were presented by median (5th–95th percentile bound-
aries). The Kaplan-Meier method was used to analyze 
survival (and recidive probability) and the long-rank test 
was used to estimate differences in survival (and recidive 
probability). Prognostic factors were examined by Cox’s 
proportional-hazards regression. All statistical values 
were considered signifi cant at the p level of < 0.05. 
Results
Patient characteristics
Median age of patients was 58.2 (40.1–72.1) years, 
range 31.9–79.9. Clinico-pathological characteristics of 
the patients are summarized in Table 1. Signifi cantly 
more patients was under 65 years old (p=0.004). Signifi -
cance was noticed in response to treatment and recurrence 
of the disease (p<0.001). Nearly 69% of all the patients 
TABLE 1
CLINICO-PATHOLOGICAL CHARACTERISTICS  OF STUDY 
SAMPLE





≥65 20 (31.2) 0.004*
Residual tumor
Absent 18 (28.2)
<1 cm 23 (35.9)








n.a. 5 (7.8) <0.001*
Recurrence of the 
disease
Yes 57 (89.1)
No 7 (10.9) <0.001*
* indicated statistical signifi cance
n.a.– not available
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had a good response to treatment, but recurrence of the 
disease was noticed in 89% of them. 
CD133 expression protein in high grade serous 
ovarian cancer and peritoneal metastasis
CD133 expression was evaluated in a series of 64 high 
grade serous ovarian carcinoma and their peritoneal me-
tastasis. Expression was mainly seen in the apical/endo-
luminal cell surface of tumor cells surrounding a lumen 
(Figure 1a and c). Cytoplasmic CD133 staining was seen 
in less than 1% of the solidly arranged tumor cells (but not 
in all positive cases) (Figure 1b). In some positive cases 
we noticed strongly stained debris in the lumina of the 
glands lined by malignant epithelium. Tumor samples 
were positive for CD133 in thirty nine cases (61%), while 
metastases were positive in twenty six cases (41%). The 
median of CD133 positive cells in tumors was 1 (0.1–7)%, 
range 0.1–9%, and in metastases was 0.6 (0.1–6)%, range 
0.1–9%. Although we noticed a more positive cases in tu-
mor samples, the difference was not statistically signifi -
cant (p>0.05). However, this result has shown a certain 
trend toward signifi cance.
 Comparing all clinico-pathological characteristics and 
the frequency of CD133 positive tumors and CD133 posi-
tive metastases, we don’t reach statistical signifi cance (all 
p>0.05, Table 2). 
CD133 expression in tumor and metastasis was classi-
fi ed into three levels: negative (0%), 0.1–0.9%, and more 
than 0.9%. Distribution of CD133 status is shown in Fig-
ure 2. We have noticed that percentage of negative cells 
are higher in metastasis than in primary tumors, in the 
group of 0.1–0.9% distribution is similar, and in group of 
higher positivity we have noticed more positive cells in 
tumor samples. The difference is signifi cant (?2=10.13, 
p=0.006).
CD117 expression protein in high grade serous 
ovarian cancer and peritoneal metastasis 
CD117 positive stain appeared as a cytoplasmic and/or 
membranous stain (Figure 1d). Nonspecifi c background 
staining of tumor stroma or adjacent ovarian parenchyma 
was not encountered. Tumor samples were positive in 
fi fty two (81%) cases, while metastases were positive in 
forty nine (77%) cases (Table 2). Although we have noticed 
Figure 1. Immunoreaction in the high grade serous ovarian cancer and metastasis. a) High CD133 expression in the high grade 
serous ovarian cancer (at the apical/endoluminal part of tumor cells). Magnifi cationx200. b) CD133 positive reaction in the 
cytoplasm of the single tumor cells. Magnifi cationx400. c) Low CD133 expression in the peritoneal metastasis (at the apical/
endoluminal part of tumor cells) Magnifi cationx200. d) CD117 positive expression in the primary serous high grade ovarian cancer 
(cytoplasmic and/or membranous stain). Magnifi cationx200.
749
S. Štemberger-Papić et al.: Expression of CD133 and CD117 in Ovarian Cancer, Coll. Antropol. 39 (2015) 3: 745–753
a more positive cases in tumor samples, the difference was 
not statistically signifi cant (p>0.05). The median of CD117 
positive cells in tumor samples was 1 (0.1–8)%, range 0.1–
22%, and in metastases was 0.1 (0.1–7)%, range 0.1–33%.
Comparing all clinico-pathological characteristics and 
the frequency of CD117 positive tumors and CD117 posi-
tive metastases, the result did not reach statistical sig-
nifi cance (all p>0.05, Table 2).  
CD117 expression in tumor and metastasis was classi-
fi ed in the same way as CD133. Distribution of CD117 
status is shown in Figure 3. We have noticed that distribu-
tion of cells are similar considering three groups and loca-
tion of positive cells, the signifi cance was not reached 
(c2=1.23, p=0.541).
Prognostic impact of CD133 and CD117 expression
We compare the disease free survival and the overall 
survival according to three levels of expression of CD133 
and CD117 in tumor and in metastasis (Table 3; Figure 
4,5,6). The median disease free survival, for all cases, was 
11 (1–62) months, range 1–79 months. For CD133 higher 
positive tumors (>0.9% of positive tumor cells) disease free 
survival was signifi cantly shorter comparing to CD133 
negative tumors and CD133 less positive tumors (0.1–
0.9% of positive tumor cells) (p=0.025). The difference in 
disease free survival between CD133 positive and CD133 
negative metastasis was not statstically significant 
(p=0.514). For CD117 higher positive cases in tumor, dis-
ease free survival was signifi cantly shorter comparing to 
CD117 negative and CD117 less positive tumor cases 
(p=0.031). The difference in disease free survival between 
TABLE 2
COMPARISON OF THE  CD133 AND CD117 POSITIVITY IN TUMOR AND IN METASTASIS  ACCORDING  TO  CLINICO-PATHOLOGICAL 
CHARACTERISTICS
Characteristics Positive  CD133 Positive  CD117
Expression  in 
tumor (n=39)
N  (%)





Expression  in 
tumor (n=52)
N  (%)






<65 26 (66.7) 15 (57.7) 0.22 33 (63.5) 31 (63.3) 0.04
≥65 13 (33.3) 11 (42.3) 0.637 19 (36.5) 18 (36.7) 0.852
Residual tumor
Absent 10 (25.6) 7 (26.9) 13 (25.0) 11 (22.4)
<1 cm 13 (33.3) 7 (26.9) 0.31 18 (34.6) 19 (38.8) 0.21
≥1 cm 16 (41.1) 12 (46.2) 0.855 21 (40.4) 19 (38.8) 0.903
Lymph node 
status
n.a. 11 (28.2) 8 (30.8) 15 (28.9) 13 (26.5)
Negative 13 (33.3) 10 (38.4) 0.09 14 (26.9) 11 (22.5) 0.17
Positive 15 (38.5) 8 (30.8) 0.763 23 (44.2) 25 (51.0) 0.683
Response to treatment  
Yes 22 (56.4) 12 (46.1) 0.32 28 (53.8) 26 (53.1) 0.04
No 17 (43.6) 14 (53.9) 0.574 24 (46.2) 23 (46.9) 0.842
Recurrence 
Yes 33 (84.6) 22 (84.6) 0.12 46 (88.5) 43 (87.8) 0.01
No 6 (15.4) 4 (15.4) 0.726 6 (11.5) 6 (12.2) 0.927
* indicated statistical signifi cance
Figure 2.  Distribution of the CD133 expression in tumor cells 
and in metastasis, ?2=10.13, p=0.006.
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Figure.3.  Distribution of the CD117 expression in  tumor cells 
and in  metastasis, c2=1.23, p=0.541.
TABLE 3
COMPARISON OF  DISEASE FREE SURVIVAL/OVERALL 
SURVIVAL ACCORDING TO  EXPRESSION OF CD133 AND CD117 
IN TUMOR(T) AND IN  METASTASIS(M)









negative 24 14 (6–73) 34 (10–90)
0.1–0.9% 7 12  (1–25) 27 (1–74)
>0.9% 27 9  (1–25) 19 (1–55)
p 0.025* 0.014*
CD133 (M)
negative 35 12 (1–73) 30 (1–74)
0.1–0.9% 12 9  (1–30) 16 (1–65)
>0.9% 11 13  (6–63) 23 (9–90)
p 0.514 0.190
CD117 (T)
negative 11 19 (8–79) 36 (9–96)
0.1–0.9% 21 12 (7–60) 27 (10–73)
>0.9% 26 9 (1–30) 19 (1–65)
p 0.031* 0.069
CD117 (M)
negative 14 13 (7–79) 32 (9–96)
0.1–0.9% 23 10 (6–27) 23 (10–74)
>0.9% 21 9 (1–36) 18 (1–64)
p 0.140 0.055
*indicated statistical signifi cante difference
CD117 positive and CD117 negative metastasis was not 
statstically  signifi cant (p=0.140).
The median overall survival was 26 (1–73) months, 
range 1–96 months. For CD133 higher positive tumors the 
median overall survival was signifi cantly shorter (19 
months), comparing to CD133 negative and CD133 less 
positive cases (34 months and 27 months, respectively) 
(p=0.014). There were no signifi cant differences in overall 
survival according to CD133 status in metastases; the 
signifi cance was not reached (P=0.190). Also, there were 
no signifi cant differences in overall survival according the 
CD117 status in tumor samples and in metastases 
(p=0.069 and p=0.055, respectively). 
Table 4. shows the results of Cox s´ proportional haz-
ards model. Comparing all clinico-pathological character-
istics and examined proteins expression, the postoperative 
survival was signifi cantly related to expression of CD133 
in tumor (p=0.024), response to treatment (p< 0.001), and 
recurrence of the disease (p< 0.001). We can identify ex-
pression of CD133 protein in tumor as independent prog-
nostic factor calculated by multivariate analysis.                                 
Discussion and Conclusion
Our study examined the possible clinical role of the 
immunohistochemically assessed expression of two poten-
tial CSC markers, CD133 and CD117,  on samples of high 
grade serous ovarian cancer and their peritoneal metas-
tases. To our knowledge, there is no data available about 
similar research.
Ovarian cancers are extremely heterogeneous, and this 
may suggest that different populations of CSCs can be 
responsible for tumorigenicity in different histological 
subtypes, although it is possible that several markers are 
expressed by the same population of ovarian CSCs7,37.So, 
we analyzed only high grade serous ovarian tumors for 
better correlation of the results. We can assume that same 
populations of the putative CSCs can express several dif-
ferent markers. Other authors considered that some over-
lap of the potential stem cell marker can occur25,28. CD133 
positivity in the tumor and in the metastasis samples was 
Figure 4. Disease free survival curves according to status of 
CD133 (T) expression, p=0.025.
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Figure 5. Disease free survival curves according to status of  
CD117 (T) expression, p=0.031.
Figure 6. Overall survival curves according to status of  
CD133 (T) expression, p=0.014.
TABLE 4
MULTIVARIATE  ANALYSIS  ASSESING THE SURVIVAL WITH  PROGNOSTIC FACTORS 
(COX PROPORTIONAL HAZARD REGRESSION)
Variables b SE P HR 95% CI za HR
CD133 (T) 0.337 0.106 0.024* 1.33 1.03–1.98
CD133 (M) 0.122 0.132 0.346 0.89 0.53–1.32
CD117 (T) 0.039 0.113 0.716 1.04 0.84–1.27
CD117 (M) 0.034 0.053 0.072 1.02 0.98–1.04
Residual tumor 0.118 0.152 0.292 0.92 0.58–1.27
Lymph node status 0.124 0.386 0.840 1.22 0.56–2.32
Reccurence of  dis. –0.055 0.022 <0.001* 0.96 0.92–0.97
Response to treatm. 0.564 0.099 <0.001* 1.82 1.42–2.12
* indicated statistical signifi cance 
(b- regression coeffi ccient, SE- Standard Error, HR- Hazard Ratio)
seen mainly at the apical/endoluminal surface, and less 
than 1% of the positive malignant cells showed diffuse 
cytoplasmic pattern. Immunohistochemically determined 
CD133 positivity expressed at the apical/endoluminal sur-
face was also noticed in samples from pancreatic ductal 
adenocarcinomas15, and ovarian carcinoma36, while Zhang 
et al. in ovarian cancer samples observed predominantly 
membrane/cytoplasmic expression18. CD117 positivity was 
noticed as a cytoplasmic and/or membranous stain in tu-
mor and in metastasis samples. Our observation is consis-
tent with data from the literature27,29.
CD133 positivity was seen in the 61% of tumors. Mae-
da et al. presents a similar results (60%)21. In other stud-
ies authors noticed higher (80%)15,19, or lower number of 
positive cases (31%)36,18, so the rank of positivity in the 
literature is quite wide. CD117 positivity was noticed in 
our study in high number of tumors, 81%, and our results 
are similar to those obtained in the literature14,35. Some 
authors noticed lower number of CD117 positive cases 
(40% and 52%,  respectively)27,29.
The CSCs provide a model of the cancer metastasis in 
which these cells are able to colonize, expand, and differ-
entiate into heterogeneous tumor phenotypes similar to 
primary tumors38. Both, the primary tumors and the me-
tastases would display similar genetic and expression 
profi les because both populations are supposedly derived 
from the same lineage of cancer stem cells32. Our results 
are in the agreement with this hypothesis, because we 
have found expression of both markers in the samples from 
tumor and from metastasis. The number of CD133 positive 
cases was somewhat higher in tumor than in metastasis, 
but the difference was not statistically signifi cant. The 
same results we obtanied for CD117. In the literature we 
did not fi nd the data for the immunohistochemically as-
sessed expression of the CD133 and CD117 for metastasis 
samples.
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In our study, the median of CD133 positive cells in 
tumor specimens was 1 (0.1–7)%, and in metastasis spec-
imens was 0.6 (0.1–6) %. The median of CD117 positive 
cells in tumors was 1 (0.1–8)%, and in metastasis was 0.1 
(0.1–6)%. These results indicate that CD133 and CD117 
could represent a possible marker for CSCs, because CSCs 
are only a very small portion, less than 5%, of the total 
tumor cell population. 
The percentage of CD133 expressing cells was signifi -
cantly higher in primary ovarian cancer than in perito-
neal metastases. Distribution of CD117 positive cells in 
tumor samples and in metastases is similar to CD133 dis-
tribution; we noticed higher percentage of CD117 positive 
cells in tumor samples, but signifi cance is not reached. 
This observation may have several reasons. There are 
studies that suggest that two forms of CSCs exists: stacio-
nary CSCs which are incorporated in tumor and persists 
in all steps of tumor progression; the other form are mobile 
CSCs that represent smaller pool of tumor cells. They are 
located at the tumor-host interface and they are capable 
to disseminate and form metastatic colonies39. Also, we 
can assume that metastasis in peritoneum cavity has dif-
ferent microenvironment than primary tumor in the ova-
ry and these different conditions may altered expression 
of potential CSCs marker. Bignotti et al. detected 156 
genes that were expressed differentially between ovarian 
serous papillary carcinomas and omental metastases40. 
Our result is with accordance with one found in the lit-
erature33. Ferrandina et al. used FACS (fl uorescence acti-
vated cell sorting) for determining the percentages of 
CD133-1 and CD133-2 in ovarian carcinoma samples and 
in omental metastases. Both the percentages of CD133-1 
and CD133-2 expressing cells were signifi cantly lower in 
omental metastases. Although the two different methods 
are used for assessment of positive cells (FACS versus 
immunohistochemistry) similar results were obtained in 
both studies.
Multivariate analysis showed that tumor expression of 
both markers has statistical signifi cance according to dis-
ease free survival. For overall survival only CD133 ex-
pression in tumor samples reached the signifi cance. The 
expression of both markers in metastasis samples didn` t 
show correlation to prognosis. 
Our immunohistochemical results show that expres-
sion of CD133 in tumor samples best correlate with prog-
nosis. Expression of both markers in metastasis samples 
has no prognostic signifi cance. Similar results for tumor 
expression were obtained by other authors18,20,21. Ferran-
dina et al. found that CD133 expression not provide ad-
ditional prognostic information for ovarian cancer patients 
at all36. But, in the large study (400 ovarian cancer pa-
tients) Zang et al. found an association between CD133 
status and prognosis18. CD133 is possibly one of the most 
reliable molecular marker for cancer stem cells in various 
solid tumors18, and CD117 has only recently been regarded 
as a possible CSCs surface marker29.
Some studies reported that CSCs phenotype was more 
resistant to platinum-based therapy, which supports the 
idea that CSCs may be responsible for chemoresistance of 
ovarian tumors and serve as chemotherapeutic targets for 
reducing disease recurrence24,25. It was hypothesized that 
CD133 and CD117 are putative marker for CSCs and de-
fi ning the methods to identify and isolate CD133 and 
CD117 positive cells in tumor can help adapting the ther-
apy to individual cases or possibly developing targeted 
therapy in the future.
Conclusion
Our study indicates that the immunohistochemical as-
sessment of CD133 and CD117 expression may have po-
tential clinical value in predicting disease progression or 
prognosis in high grade serous ovarian cancer patients. 
According to our results, CD133 proved to be an indepen-
dent prognostic factor in high grade serous ovarian cancer 
patients.
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IZRAŽAJ BILJEGA CD133 I CD117 U 64 BOLESNICE SA SEROZNIM RAKOM JAJNIKA
S A Ž E T A K
Tumorske matične stanice (cancer stem cells-CSCs) predstavljaju manji dio stanica u tumoru koje se mogu samoob-
navljati i proliferirati, te su vjerojatno odgovorne za početak i održavanje tumorskog rasta. CD133 i CD117 su najčešće 
korišteni biljezi za potencijalne CSCs,  osobito za CSCs jajnika, no njihov klinički značaj još uvijek je nedovoljno istražen. 
Cilj ovog istraživanja bio je usporediti imunohistokemijski izražaj biljega CD133 i CD117 kod 64 slučaja primarnog se-
roznog raka jajnika visokog gradusa i pripadajućih peritonealnih metastaza, te ispitati njihovu  potencijalnu kliničku 
ulogu. Izražaj biljega CD133 uočen je u apikalnim/ endoluminalnim  dijelovima tumorskih stanica, u 61% tumora i 41% 
metastaza. Medijan CD133 pozitivnih stanica u tumorima bio je 1 (0,1–7)%, a u metastazama 0,6 (0,1–6)%. Izražaj 
biljega CD117 uočen je kao citoplazmatsko i/ili membransko bojenje, a pronađeno je u 81% tumora i 77% metastaza. 
Medijan CD117 pozitivnih stanica u tumorima bio je 1 (0,1–8)%, a u metastazama 0,1 (0,1–6)%. Multivarijatna analiza 
pokazala je da bolesnice s jačim izražajem biljega CD133 u tumoru imaju statistički značajno kraće vrijeme do pojave 
recidiva i vrijeme preživljenja (p=0,025 odnosno p=0,014). Bolsnice s jačim izražajem biljega CD117 u tumoru imaju 
statistički značajno kraće vrijeme do pojave recidiva bolesti (P = 0,031). Cox-ovom regresijskom metodom izražaj biljega 
CD133 u tumoru uočen je kao nezavisni prognostički čimbenik. Naša studija pokazuje da imunohistokemijski izražaj 
biljega CD133 i CD117 može imati potencijalnu kliničku vrijednost u predviđanju progresije bolesti i prognoze kod sero-
znog raka jajnika visokog gradusa. Izražaj biljega CD133 je nezavisni prognostički čimbenik kod pacijenata sa seroznim 
rakom jajnika visokog gradusa.
